RHA® 4 NLF Cannula

NCT04754646 | Completed Results FDA Device

• 1 other identifier: TEO-RHA-2001
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 4

Brief Summary

This is a randomized, controlled, single-blinded, within-subject (split-face), multicenter, prospective study to investigate whether RHA®4 injected in NLFs with a cannula is non-inferior to RHA®4 injected in NLFs with a sharp needle (27G x ½") for the correction of moderate to severe NLFs as determined by the Blinded Live Evaluator (BLE) using the Teoxyne NLF-WSRS (proprietary, validated NLF Wrinkle Severity Rating Scale) at 12 weeks from last treatment. At Visit 1 (Week 0), RHA®4 injected with cannula will be administered in a random sequence (first or second injection) and side of the face (left or right NLF) and RHA®4 injected with a sharp needle will be administered to the other side. The TI will administer study devices and will be unblinded to treatment allocation. Blinded assessments of effectiveness will be conducted by the BLE (Blinded Live Evaluator). 4 weeks following initial treatment, subjects will attend Visit 2 and receive, if necessary, touch-up treatments (using a needle or cannula as per the subject's initial treatment assignment). Subjects receiving touch-up treatments at Week 4 (Visit 2) will attend a new Visit 2b (4 weeks following touch-up treatment); subject not receiving touch-up treatment will not attend Visit 2b. After each injection (initial treatment or touch-up), subjects will receive a safety follow-up call from the study site within 3-day. Subjects will then attend scheduled in-office study visits at 8 (Visit 3) and 12 weeks (Visit 4) following last treatment (initial treatment or touch-up) where safety and effectiveness assessments will be conducted.

Conditions

Wrinkle; Nasolabial Fold; Aging

Keywords

Dermal Filler; Hyaluronic acid; Cannula; Nasolabial folds

Outcome Measures

Primary Outcomes (1)

• Change in NLF-WSRS Score Between Baseline and Week 12 After Last Treatment as Assessed by the BLE

  Non-inferiority of RHA®4 injected with a cannula to the change from Baseline for subjects treated with RHA®4 injected with a needle at 12 weeks after last treatment (initial or touch-up; up to 16 weeks post-baseline)) as assessed by the BLE using the NLF-WSRS. NLF-WSRS (Nasolabial Folds - Wrinkle Severity Rating Scale) is a proprietary validated 5-grade scale with 1 being "Absent" and 5 being "Extreme". An NLF-WSRS change of \>1 grade will be considered clinically significant.

  Week 12 after last treatment

Secondary Outcomes (16)

• Change in Score From Baseline in the Nasolabial Folds Severity Rated by the Treating Investigator (TI) at Weeks 4, 8 and 12 After Last Treatment Using the NLF-WSRS.

  Weeks 4, 8 and 12 after last treatment

• Number of Responders (Change of ≥1-grade From Baseline in the Naso-labial Folds Severity) as Assessed by the Blinded Live Evaluator (BLE) at Week 12 After Last Treatment Using the NLF-WSRS.

  Week 12 after last treatment

• Number of Responders (Change of ≥1-grade From Baseline in the Naso-labial Folds Severity) as Assessed by the Treating Investigator (TI) at Weeks 4, 8 and 12 After Last Treatment Using the NLF-WSRS.

  Weeks 4, 8 and 12 after last treatment

• Number of Subjects Scored Either "Much Improved" or "Improved" on Global Aesthetic Improvement (GAI) Scale by the Blinded Live Evaluator (BLE) at 12 Weeks Following Last Treatment.

  Week 12 after last treatment

• Number of Subjects Scored Either "Much Improved" or "Improved" on Global Aesthetic Improvement (GAI) Scale by the Treating Investigator (TI) at 4, 8 and 12 Weeks Following Last Treatment.

  Weeks 4, 8 and 12 after last treatment

Study Arms (2)

RHA®4 - Cannula

EXPERIMENTAL

Device: Split-face injection of RHA® 4 with a cannula into a single NLF.

RHA®4 - Needle

ACTIVE COMPARATOR

Device: Split-face injection of RHA® 4 with a needle (TSK 27G x ½") into the contralateral NLF.

Interventions

Split-face injection of RHA® 4 with a cannula into a single NLF. DEVICE

RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF). The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA.

RHA®4 - Cannula

Split-face injection of RHA® 4 with a needle (TSK 27G x ½") into the contralateral NLF. DEVICE

RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).

RHA®4 - Needle

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Outpatient, male or female of any race, 22 years of age or older.
• Female subjects of childbearing potential must have a negative UPT and practice a reliable method of contraception throughout the study.
• Moderate to severe bilateral nasolabial folds (grade 3 or 4 on the five-point NLF-WSRS). BLE and TI must independently agree that the criterion is met; however, strict concordance of severity not required. BLE assessments will be used for the primary endpoint. If TI and BLE do not agree on eligibility, or if their assessments differ by ≥2 grades, the subject will not be eligible.
• Nasolabial folds of the same NLF-WSRS grade on the left and right sides of the face.
• Willing to abstain from facial aesthetic procedures/therapies that could interfere with the study evaluations.
• Able to follow study instructions and complete all required visits.
• Sign the IRB-approved ICF, Photographic Release Form, the Authorization for Use and release of Health and Research Study Information (HIPAA) form, and if applicable, the California Experimental Research Subject's Bill of Rights prior to any study-related procedures being performed.

You may not qualify if:

• Known hypersensitivity or previous allergic reaction to any component of the study devices.
• Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, or history of anaphylactic shock.
• History of active chronic debilitating systemic disease that, in the opinion of the investigator, would make the subject a poor candidate in the study.
• History of connective tissue disease.
• Malignancy (excluding non-melanoma skin cancer) within the past 5 years.
• History of skin cancer in the treatment area.
• Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
• Exposure to any other investigational drug/device within 90 days of entering the study or planning to participate in another investigation during the course of the study.
• Study staff or close relative to study staff (e.g., parents, children, siblings, or spouse)

Sponsors & Collaborators

• Teoxane SA: lead

Study Sites (4)

United States, California

Encinitas, California, 92024, United States

Location

United States, Florida

West Palm Beach, Florida, 33401, United States

Location

United States, North Carolina

Chapel Hill, North Carolina, 27517, United States

Location

United States, Tennessee

Nashville, Tennessee, 37203, United States

Location

Results Point of Contact

• Title: Clinical Project Manager
• Organization: TEOXANE SA

clinical@teoxane.com

+41(0) 22 344 96 36

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Blinded-Live Evaluator
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 8, 2021
• First Posted: February 15, 2021
• Study Start: March 15, 2021
• Primary Completion: August 17, 2021
• Study Completion: November 29, 2021
• Last Updated: March 9, 2023
• Results First Posted: March 9, 2023

Record last verified: 2023-03

Locations

US (4)